Segra International | Dr. Kevin Kjernisted Joins Segra Advisory Board
Segra International is a specialist R&D company focused on Quality Management Systems and facilities for medicinal Cannabis and botanical tissue culture
Segra, Research and Development, R&D, Quality Management Systems, facilities, plant-based medicines, medicinal, Cannabis, botanical, tissue culture, specialist, Genotyping Services, Tissue Culture Production, Modular Growing Facility
164
post-template-default,single,single-post,postid-164,single-format-standard,ajax_fade,page_not_loaded,,footer_responsive_adv,qode-child-theme-ver-1.0.0,qode-theme-ver-10.1.1,wpb-js-composer js-comp-ver-5.0.1,vc_responsive
 

Dr. Kevin Kjernisted Joins Segra Advisory Board

PRESS RELEASES

Dr. Kevin Kjernisted Joins Segra Advisory Board

Vancouver, BC, January 20, 2016 – Segra Biogenesis Corp is pleased to announce the appointment of Dr. Kevin Kjernisted, M.D., FRCPC, a clinical psychiatry specialist to the advisory board.

Dr. Kjernisted received his Medical Degree from the University of Manitoba in 1983. He worked as a general practitioner for five years before completing training to be a psychiatrist at the University of Manitoba. For more than a decade Dr. Kjernisted was Medical Director of the Anxiety Disorders Clinic and Director of Research at St. Boniface General Hospital in the Department of Psychiatry, University of Manitoba before relocating to Vancouver, where he is currently a Clinical Associate Professor of Psychiatry in the Faculty of Medicine at the University of British Columbia. Dr. Kjernisted has acted as principal investigator in over 35 clinical trials investigating compounds for mood disorders, anxiety disorders, schizophrenia, ADHD and weight management. His research interests also include the “mind-body connection” which involves interactions between the brain, the gut and the immune system (psychoneuroimmunology). Dr. Kjernisted has lectured extensively on this topic to peers at national and international meetings. Optimal treatment in his busy clinical practice involves complementary and alternative treatments including probiotics, exercise and nutraceuticals, along with medications and psychotherapy, in order to address excessive inflammation and oxidation which contribute to psychiatric illness, chronic pain, heart disease, liver disease, diabetes, inflammatory bowel disease, cancer and dementia.

At Segra, we believe in basing our product claims for efficacy and safety on validated scientific research, and in being transparent about the sources of the research with our customers. With the appointment of Dr. Kjernisted to the advisory board, the Company will be in a better position to develop clinical trials and validated research according to Company principles. For more information on the Segra management and advisory team visit http://segra-intl.com/team/.

Segra Biogenesis Corp. is an emerging specialist Research and Development Company focused on plantbased medicines, including medicinal Cannabis. Our team is driven by its experience in research and development work in medicine, genetics, cultivation techniques, natural medicines, biochemistry, agriculture and information technology. Segra’s goal is to research, develop, test and produce very unique and specific cultivars from the plant kingdom that are effective for specific ailments in medical patients.

Segra Biogenesis Corp
www.segra-intl.com

For Information Contact:
Todd McMurray
President
Email:todd@segra-intl.com